See more : Brisbane Broncos Limited (BBL.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Interpace Biosciences, Inc. (IDXG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Interpace Biosciences, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Concord Acquisition Corp II WT (CNDA-WT) Income Statement Analysis – Financial Results
- Cigna Corporation (CI) Income Statement Analysis – Financial Results
- Westwater Resources, Inc. (WWR) Income Statement Analysis – Financial Results
- Worldwide Webb Acquisition Corp. (WWACW) Income Statement Analysis – Financial Results
- Next Science Limited (NXS.AX) Income Statement Analysis – Financial Results
Interpace Biosciences, Inc. (IDXG)
About Interpace Biosciences, Inc.
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 40.21M | 31.84M | 41.31M | 32.40M | 24.08M | 21.90M | 15.90M | 13.09M | 9.43M | 119.94M | 150.84M | 126.90M | 157.29M | 144.65M | 84.87M | 112.53M | 117.13M | 239.24M | 319.42M | 364.44M | 317.45M | 284.01M | 696.58M | 416.88M | 174.90M | 101.10M | 54.70M |
| Cost of Revenue | 16.31M | 13.61M | 23.37M | 21.67M | 15.89M | 10.20M | 7.36M | 6.64M | 6.91M | 101.39M | 126.43M | 100.04M | 124.82M | 112.45M | 58.59M | 108.02M | 85.52M | 183.40M | 257.48M | 265.61M | 228.37M | 254.14M | 560.80M | 302.28M | 128.90M | 77.70M | 44.30M |
| Gross Profit | 23.90M | 18.23M | 17.95M | 10.73M | 8.19M | 11.70M | 8.54M | 6.44M | 2.52M | 18.54M | 24.41M | 26.86M | 32.47M | 32.20M | 26.28M | 4.51M | 31.62M | 55.84M | 61.94M | 98.83M | 89.08M | 29.87M | 135.78M | 114.60M | 46.00M | 23.40M | 10.40M |
| Gross Profit Ratio | 59.44% | 57.26% | 43.44% | 33.10% | 34.02% | 53.43% | 53.71% | 49.25% | 26.74% | 15.46% | 16.18% | 21.17% | 20.64% | 22.26% | 30.96% | 4.01% | 26.99% | 23.34% | 19.39% | 27.12% | 28.06% | 10.52% | 19.49% | 27.49% | 26.30% | 23.15% | 19.01% |
| Research & Development | 636.00K | 703.00K | 1.88M | 2.80M | 2.81M | 2.12M | 1.46M | 1.65M | 2.29M | 255.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 9.36M | 10.97M | 13.67M | 20.77M | 14.55M | 8.50M | 9.15M | 10.50M | 16.92M | 29.15M | 28.69M | 27.87M | 34.28M | 36.51M | 48.74M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 10.23M | 9.13M | 10.07M | 9.25M | 11.12M | 8.42M | 6.57M | 5.46M | 10.36M | 604.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.60M | 20.10M | 23.74M | 30.02M | 25.66M | 16.92M | 15.72M | 15.97M | 27.28M | 29.15M | 28.69M | 27.87M | 34.28M | 36.51M | 48.74M | 39.37M | 44.83M | 50.69M | 88.82M | 63.64M | 67.25M | 76.83M | 123.08M | 71.65M | 29.10M | 13.90M | 7.90M |
| Other Expenses | 868.00K | 1.27M | 4.06M | 4.46M | 3.65M | 263.00K | -2.13M | 14.00K | -93.00K | -68.00K | -59.00K | -28.00K | 2.89M | 20.57M | 0.00 | 333.00K | 1.06M | -3.28M | 53.49M | 0.00 | 2.10M | 0.00 | 0.00 | 2.08M | 1.20M | 300.00K | 100.00K |
| Operating Expenses | 20.23M | 22.07M | 29.68M | 37.28M | 32.12M | 22.30M | 20.43M | 21.38M | 33.38M | 29.93M | 28.69M | 27.87M | 37.17M | 36.51M | 48.74M | 39.70M | 45.90M | 47.41M | 88.82M | 63.64M | 69.35M | 76.83M | 123.08M | 73.72M | 30.30M | 14.20M | 8.00M |
| Cost & Expenses | 37.41M | 35.68M | 53.05M | 58.95M | 48.01M | 32.49M | 27.79M | 28.02M | 40.29M | 131.32M | 155.12M | 127.91M | 161.99M | 148.96M | 107.33M | 147.72M | 131.41M | 230.80M | 346.30M | 329.25M | 297.72M | 330.97M | 683.88M | 376.00M | 159.20M | 91.90M | 52.30M |
| Interest Income | 0.00 | 1.01M | 1.04M | 549.00K | 440.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.74M | 3.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.01M | 1.01M | 920.00K | 549.00K | 440.00K | 331.00K | 433.00K | 2.14M | 3.71M | 602.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.03M | 2.56M | 5.37M | 5.50M | 4.52M | 3.80M | 3.69M | 4.27M | 5.03M | 2.39M | 1.43M | 2.03M | 3.05M | 1.98M | 2.84M | 4.61M | 5.61M | 5.76M | 5.82M | 5.92M | 6.80M | 7.82M | 4.99M | 2.08M | 1.20M | 300.00K | 100.00K |
| EBITDA | 3.84M | -2.27M | -1.33M | -20.10M | -21.72M | -8.57M | -9.01M | -2.16M | -35.47M | -13.35M | -212.00K | 725.00K | -1.67M | -3.08M | -14.16M | -28.97M | -8.67M | 16.42M | -5.39M | 41.89M | 28.08M | -39.59M | 17.70M | 42.95M | 16.90M | 10.00M | 3.00M |
| EBITDA Ratio | 9.54% | -11.88% | -19.80% | -66.75% | -83.41% | -32.34% | -67.75% | -85.25% | -274.86% | -7.55% | -1.89% | 19.90% | -1.04% | -1.71% | -5.33% | -25.78% | -6.50% | 5.62% | -7.99% | 11.07% | 8.73% | -13.34% | 2.21% | 9.14% | 8.35% | 7.42% | 16.45% |
| Operating Income | 2.80M | -3.84M | -11.74M | -26.56M | -23.93M | -12.12M | -6.29M | -6.44M | -40.41M | -13.47M | -4.28M | -25.23M | -4.70M | -4.31M | -40.58M | -36.43M | -14.28M | 5.91M | -26.89M | 35.19M | 19.59M | -50.18M | 12.71M | 40.88M | 15.70M | 9.20M | 2.40M |
| Operating Income Ratio | 6.97% | -12.06% | -28.41% | -81.96% | -99.39% | -55.35% | -39.59% | -49.23% | -428.41% | -11.23% | -2.84% | -19.88% | -2.99% | -2.98% | -47.81% | -32.37% | -12.19% | 2.47% | -8.42% | 9.66% | 6.17% | -17.67% | 1.82% | 9.81% | 8.98% | 9.10% | 4.39% |
| Total Other Income/Expenses | -1.68M | -2.22M | -1.41M | -82.00K | -244.00K | -582.00K | -6.84M | -2.13M | -3.80M | -670.00K | -2.90M | -24.25M | -939.00K | 414.00K | -26.89M | 2.51M | 4.68M | 4.74M | 15.68M | 1.89M | -1.03M | 1.97M | 2.28M | 4.86M | 2.20M | 2.00M | -6.20M |
| Income Before Tax | 1.13M | -5.84M | -15.41M | -26.15M | -26.67M | -12.19M | -13.13M | -8.57M | -44.21M | -14.14M | -4.34M | -25.26M | -4.72M | -4.17M | -40.39M | -33.59M | -8.21M | 10.65M | -19.25M | 35.97M | 20.66M | -48.21M | 14.98M | 45.74M | 17.90M | 11.20M | -4.10M |
| Income Before Tax Ratio | 2.81% | -18.33% | -37.31% | -80.71% | -110.75% | -55.66% | -82.61% | -65.51% | -468.68% | -11.79% | -2.87% | -19.91% | -3.00% | -2.88% | -47.59% | -29.85% | -7.01% | 4.45% | -6.03% | 9.87% | 6.51% | -16.97% | 2.15% | 10.97% | 10.23% | 11.08% | -7.50% |
| Income Tax Expense | 17.00K | 29.00K | -667.00K | 53.00K | -28.00K | 18.00K | -395.00K | -162.00K | -13.14M | -4.74M | 180.00K | 208.00K | -939.00K | 414.00K | -6.83M | 875.00K | 1.77M | -724.00K | 201.00K | 14.84M | 8.41M | -17.45M | 8.63M | 18.71M | 7.50M | 1.70M | 6.60M |
| Net Income | 802.00K | -5.87M | -14.75M | -26.20M | -26.64M | -12.19M | -12.22M | -8.33M | -11.36M | -16.07M | -4.57M | -25.53M | -11.91M | -6.81M | -33.56M | -34.46M | -9.97M | 11.81M | -19.45M | 21.13M | 12.26M | -30.76M | 6.35M | 27.03M | 10.40M | 9.50M | -4.20M |
| Net Income Ratio | 1.99% | -18.42% | -35.69% | -80.87% | -110.63% | -55.67% | -76.84% | -63.68% | -120.40% | -13.40% | -3.03% | -20.12% | -7.57% | -4.71% | -39.54% | -30.62% | -8.52% | 4.94% | -6.09% | 5.80% | 3.86% | -10.83% | 0.91% | 6.48% | 5.95% | 9.40% | -7.68% |
| EPS | 0.19 | -1.38 | -3.57 | -6.50 | -7.11 | -4.33 | -7.77 | -45.88 | -73.38 | -107.87 | -3.10 | -17.50 | -8.25 | -4.76 | -23.60 | -24.20 | -7.15 | 8.50 | -13.67 | 14.00 | 8.40 | -21.92 | 4.60 | 20.00 | 8.70 | 9.20 | -4.86 |
| EPS Diluted | 0.18 | -1.38 | -3.57 | -6.50 | -7.11 | -4.33 | -7.75 | -45.88 | -73.36 | -107.87 | -3.10 | -17.50 | -8.25 | -4.76 | -23.60 | -24.20 | -7.15 | 8.40 | -13.67 | 13.70 | 8.30 | -21.92 | 4.50 | 19.60 | 8.60 | 9.10 | -4.86 |
| Weighted Avg Shares Out | 4.32M | 4.24M | 4.14M | 4.03M | 3.75M | 2.82M | 1.57M | 181.60K | 154.75K | 149.01K | 1.47M | 1.46M | 1.44M | 1.43M | 1.42M | 1.42M | 1.39M | 1.39M | 1.42M | 1.46M | 1.42M | 1.40M | 1.39M | 1.35M | 1.20M | 1.07M | 863.64K |
| Weighted Avg Shares Out (Dil) | 4.36M | 4.24M | 4.14M | 4.03M | 3.75M | 2.82M | 1.58M | 181.60K | 154.80K | 149.01K | 1.47M | 1.46M | 1.44M | 1.43M | 1.42M | 1.42M | 1.39M | 1.40M | 1.42M | 1.49M | 1.44M | 1.40M | 1.41M | 1.38M | 1.22M | 1.08M | 863.64K |
Interpace Biosciences Announces Record Third Quarter 2024 Financial and Business Results
PARSIPPANY, NJ, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the third quarter ended September 30, 2024 and provided a business and financial update.
Interpace Biosciences Announces Capital Restructuring of Its Preferred Stock as a First Step Toward Seeking an Uplisting of Its Common Stock to Nasdaq
PARSIPPANY, NJ, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that its Series B Preferred Stock investors, Ampersand Capital Partners and 1315 Capital (the “Investors”), have exchanged (the “Exchange”) their existing...
Interpace Biosciences Announces Record Second Quarter 2024 Financial and Business Results
PARSIPPANY, NJ, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the second quarter ended June 30, 2024 and provided a business and financial update.
Interpace Diagnostics® Announces Undefined Extension of Medicare Coverage for PancraGEN®, a Molecular Diagnostic Test That Assesses Cancer Risk of Pancreatic Cysts
PARSIPPANY, NJ, July 29, 2024 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX: IDXG) today responded to the undefined extension granted by Centers for Medicare & Medicaid Services (CMS) to Novitas, its Medicare...
Interpace Biosciences Announces First Quarter 2024 Financial and Business Results
PARSIPPANY, NJ, May 09, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2024 and provided a business and financial update.
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results
PARSIPPANY, NJ, March 07, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fourth quarter and full year ending December 31, 2023.
Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results
PARSIPPANY, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the third quarter ended September 30, 2023 and provided a business and financial update.
Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results
PARSIPPANY, NJ, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the second quarter ended June 30, 2023 and provided a business and financial update.
Interpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN® Reimbursement
PARSIPPANY, NJ, July 10, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced preliminary business results for the second quarter ending June 30, 2023, and provided an update on recent activities. Final Q2 financial...
Interpace Biosciences Announces New $7.5 Million Credit Facility with Comerica Bank
PARSIPPANY, NJ, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it, along with its subsidiaries, has entered into a new $7.5 Million revolving credit facility with Comerica Bank (the “Bank”)....
Source: https://incomestatements.info
Category: Stock Reports